REIMBURSEMENT 
I will not receive any financial reimbursement for my participation in this study. 
TREATMENT AND COMPENSATION FOR INJURY 
IH am injured as a result of being in this study, treatment will be available. If I am eligible 
for veteran's benefits, the costs of such treatment will be covered by the Department of 
Veterans Affairs. If not, the costs of such treatment may be covered by the Department of 
Veterans Affairs or the University of California, depending on a number of factors. The 
Department of Veterans Affairs and the University do not normally provide any other form 
of compensation for injury. For further information about this, I may call the V.A. District 
Counsel at (415) 750-2288 or the office of the UCSF Committee on Human Research at 
(415) 476-1814. 
NEW FINDINGS 
I and my family will be given any new information gained during the course of the study 
which might affect my willingness to continue my participadon. 
CONFIDENTIALITY 
Participadon in research may involve a loss of privacy. The results of all study tests will be 
discussed with myself and my own doctor. My medical records at UCSF will be considered 
confidendal and used only for medical and/or research purposes. My idendty will be kept as 
confidendal as possible, and I will not be idendfied in any report or publicadon of this study or 
its results. Representadves from the sponsoring drug company (Canji, Inc., San Diego, CA), 
the Nadonal Cancer Institute, and the Food and Drug Administration (FDA) of the United 
States may review information about me to check on the study. 
Research studies involving gene therapy have received a great deal of attention from the 
media. Although every effort will be made to protect the confidentiality of myself and my 
family, this media attention may result in a greater risk than usual that information 
concerning my treatment will appear publicly without my consent. 
QUESTIONS 
Dr. , who can be reached at telephone number , has 
discussed this study with me. I have the right to ask questions regarding the study. I have been 
given the opportunity to ask questions, and they have been answered to my satisfaction. If I have 
any further questions regarding this study or I experience any health-related problems, I should 
contact Dr. Alan Venook or associates at (415) 476-1421 or Dr. Robert Warren or associates at 
(415) 476-1161. 
Recombinant DNA Research, Volume 20 
[701] 
